Atorvastatin Dibromo Impurity
✓
100 % Datengenauigkeit
Wissenschaftlicher Support rund um die Uhr
⬡
0 % Toleranz bei der Produktqualität

Lagerstandorte

  • New Jersey, USA
  • Czech Republic, EU
  • Mumbai, India

* Vorbehaltlich Verfügbarkeit

Dokumentation

MSDS herunterladen

Beispiel-COA herunterladen

Enthält: HPLC, MASS/LC-MS, 1H-NMR, FT-IR, Gehalt, Structure Elucidation Report (SER) sowie zusätzliche analytische Daten je nach Produkt.

2514955-94-1Atorvastatin Dibromo Impurity

● Auf Lager

Katalog-Nr.::VE008631
CAS-Nr.::2514955-94-1
Summenformel::C14H9Br2FO
Molare Masse::372.03 g/mol

Zusätzliche Informationen zu CAS 2514955-94-1

Parent drug

Atorvastatin

IUPAC-Name

2, 2-Dibromo-1-(4-fluorophenyl)-2-phenylethanone

Synonyme

N/A

SMILES

O=C(C1=CC=C(F)C=C1)C(Br)(Br)C2=CC=CC=C2

Beschreibung

It is oral antilipemic drug atorvastatin that reversibly inhibits HMG-CoA reductase. It raises plasma concentrations of HDL-C while decreasing levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), apolipoprotein B, non-high-density lipoprotein cholesterol (non-HDL-C), and triglyceride (TG). Atherosclerosis and cardiovascular disease are related to high LDL-C, low HDL-C, and high TG concentrations in the plasma. A major indicator of coronary artery disease is the ratio of total cholesterol to HDL-C, and greater ratios are linked to a higher risk of the condition. Lower cardiovascular risk is linked to higher HDL-C levels. A statin like atorvastatin lowers the risk of cardiovascular morbidity and death by lowering LDL-C and TG and raising HDL-C.

References

McIver, Lindsey A., and Momin S. Siddique. “Atorvastatin.” Nih.gov, StatPearls Publishing, 15 May 2022, www.ncbi.nlm.nih.gov/books/NBK430779/.

Angebot anfordern

„*“ zeigt erforderliche Felder an

Dieses Feld dient zur Validierung und sollte nicht verändert werden.
Products quotation
Name
Url